Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Meeting

9 Mar 2020 11:07

RNS Number : 4455F
4d Pharma PLC
09 March 2020
 

4D pharma plc

 

("4D pharma" or the "Company")

 

Result of General Meeting

 

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutic products, announces that, at the General Meeting held earlier today to enable the proposed issue of a total of 44,000,000 New Ordinary Shares in connection with the Placing and Subscription to raise gross proceeds of £22 million, all Resolutions were duly passed.

 

Further to the Result of Placing announcement made on 18 February 2020, 27,176,920 Subscription Shares and 16,823,080 Placing Shares will be issued. The total number of New Ordinary Shares to be issued pursuant to the Subscription and Placing remains unchanged.

Application has been made to the London Stock Exchange for the 44,000,000 New Ordinary Shares to be admitted to trading on AIM and it is expected that Admission will occur and dealings commence at 8.00 a.m. tomorrow, 10 March 2020.

Total Voting Rights

Following Admission, the Company will have 109,493,842 Ordinary Shares in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. There Company holds no Ordinary Shares in treasury.

Block Admission

A block admission has been made in respect of 22,000,000 shares which may arise from the exercise of Warrants issued in connection with the Fundraising ("Warrant Shares") under the scheme name '4D March 2020 Warrants'. Admission of the block listed shares will also take effect on 10 March 2020. For the avoidance of doubt, the Warrants themselves will not be admitted to Trading on AIM. Each Warrant entitles the holder to subscribe for one Ordinary Share at a price of 100 pence at any time up to 10 March 2025.

 

Definitions

 

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to them in the announcement made by the Company on 18 February 2020 to announce the launch of the Placing.

 

 

For further information please contact:

4D

 

Duncan Peyton, Chief Executive Officer

ir@4dpharmaplc.com

+ 44 (0)113 895 0130

 

 

N+1 Singer - Nominated Adviser, Joint Bookrunner and Joint Broker

+44 (0) 20 7496 3000

Aubrey Powell / Justin McKeegan / Alex Bond (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

 

Bryan Garnier & Co. Limited - Joint Bookrunner and Joint Broker

+44 (0)20 7332 2500

Dominic Wilson / Phil Walker

 

Chardan - US Placing Agent

David Lederman (Equity Capital Markets)

+1 646 465-9011

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMJLMBTMTMMBFM
Date   Source Headline
9th Nov 20201:00 pmRNSSITC data MRx0518 monotherapy and combination
5th Nov 202012:00 pmRNSVirtual KOL Event SITC Data
30th Oct 20204:57 pmRNSHolding(s) in Company
23rd Oct 20201:17 pmRNSHolding(s) in Company
22nd Oct 20207:00 amRNSProposed Merger & Intention to seek NASDAQ Listing
14th Oct 202010:09 amRNSHolding(s) in Company
14th Oct 20207:00 amRNSPresentations on MRx0518 at SITC 2020
12th Oct 20202:01 pmRNSHolding(s) in Company
7th Oct 20207:00 amRNSTopline Results for Blautix phase II trial
30th Sep 20207:00 amRNSInterim Results
23rd Sep 20207:00 amRNSDirectorate Change
14th Sep 20204:30 pmRNSBlock Listing Six Monthly Return
7th Sep 20205:26 pmRNSHolding(s) in Company
1st Sep 20204:58 pmRNS4D hosts virtual R&D event
26th Aug 20207:00 amRNSMRx0158 Keytruda Part A clinical benefit data
14th Aug 20204:49 pmRNSHolding(s) in Company
12th Aug 20207:00 amRNSHolding(s) in Company
28th Jul 202010:34 amRNSHolding(s) in Company
24th Jul 20204:58 pmRNSHolding(s) in Company
20th Jul 20205:09 pmRNSHolding(s) in Company
16th Jul 20206:15 pmRNSHolding(s) in Company
16th Jul 20204:43 pmRNSHolding(s) in Company
15th Jul 20204:16 pmRNSHolding(s) in Company
13th Jul 20205:57 pmRNSResult of Fundraising
13th Jul 202012:13 pmRNSPlacing and Subscription of £7.7m
6th Jul 20207:00 amRNSOncology Clinical Update
2nd Jul 20204:02 pmRNSHolding(s) in Company
2nd Jul 20207:00 amRNSCOVID-19 study open for enrolment
30th Jun 20201:05 pmRNSResult of AGM
25th Jun 20207:00 amRNSHolding(s) in Company
22nd Jun 202011:19 amRNSHolding(s) in Company
10th Jun 20205:25 pmRNSHolding(s) in Company
10th Jun 20205:17 pmRNSHolding(s) in Company
10th Jun 202011:21 amRNSHolding(s) in Company
5th Jun 20201:00 pmRNSAnnual Report and Notice of AGM
5th Jun 20207:41 amRNS4D hosts virtual R&D event
26th May 20207:00 amRNSFinal Results
21st May 20207:00 amRNSDirectorate Change
19th May 20206:20 pmRNSHolding(s) in Company
12th May 20206:06 pmRNSHolding(s) in Company
11th May 20207:00 amRNSCompletion of immuno-oncology study safety phase
24th Apr 202011:30 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSPhase II study in COVID-19
17th Apr 20207:00 amRNSAppointment of Non-Executive Chairperson
17th Apr 20207:00 amRNSInterim analysis of Blautix phase II study data
30th Mar 202012:08 pmRNSSecond Price Monitoring Extn
30th Mar 202012:03 pmRNSPrice Monitoring Extension
19th Mar 20204:36 pmRNSPrice Monitoring Extension
19th Mar 20209:47 amRNSHolding(s) in Company
18th Mar 20204:44 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.